AIMS: To determine plasma levels of apoprotein (apo) C-II and apoprotein C-III in Type 2 diabetic patients and to examine the clinical and biological factors that are associated with elevated apoC concentrations. METHODS: We measured apoC-II and apoC-III in total plasma and in non-high-density lipoprotein fractions by an immunoturbidimetric assay in 88 Caucasian Type 2 diabetic patients and in 138 healthy control subjects. RESULTS: Plasma levels of both apoC-II and apoC-III were increased in Type 2 diabetic patients. The clinical conditions associated with an increase of plasma apoC-II and apoC-III were abdominal obesity, body mass index, poor glycaemic control and lack of insulin treatment. However, when multivariate analysis was used, plasma apoCs levels correlated with triglyceride levels only. The apoC-III/apoC-II ratio was similar in the Type 2 diabetic and control subjects. CONCLUSIONS: Our study shows the parallel increase of apoC-II and C-III in Type 2 diabetic patients. This parallel increase is related to hypertriglyceridaemia only.
AIMS: To determine plasma levels of apoprotein (apo) C-II and apoprotein C-III in Type 2 diabeticpatients and to examine the clinical and biological factors that are associated with elevated apoC concentrations. METHODS: We measured apoC-II and apoC-III in total plasma and in non-high-density lipoprotein fractions by an immunoturbidimetric assay in 88 Caucasian Type 2 diabeticpatients and in 138 healthy control subjects. RESULTS: Plasma levels of both apoC-II and apoC-III were increased in Type 2 diabeticpatients. The clinical conditions associated with an increase of plasma apoC-II and apoC-III were abdominal obesity, body mass index, poor glycaemic control and lack of insulin treatment. However, when multivariate analysis was used, plasma apoCs levels correlated with triglyceride levels only. The apoC-III/apoC-II ratio was similar in the Type 2 diabetic and control subjects. CONCLUSIONS: Our study shows the parallel increase of apoC-II and C-III in Type 2 diabeticpatients. This parallel increase is related to hypertriglyceridaemia only.
Authors: Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley Journal: Atherosclerosis Date: 2017-10-20 Impact factor: 5.162
Authors: Troels Mygind Jensen; Daniel R Witte; Damiana Pieragostino; James N McGuire; Ellis D Schjerning; Chiara Nardi; Andrea Urbani; Mika Kivimäki; Eric J Brunner; Adam G Tabàk; Dorte Vistisen Journal: Acta Diabetol Date: 2012-02-05 Impact factor: 4.280
Authors: Juan-Patricio Nogueira; Marie Maraninchi; Sophie Béliard; Anne Marie Lorec; Bruno Berthet; Audrey Bégu-Le Corroller; Noémie Dubois; Rachel Grangeot; Catherine Mattei; Jean Gaudart; Alain Nicolay; Henri Portugal; Bernard Vialettes; René Valéro Journal: Nutr Metab (Lond) Date: 2012-03-13 Impact factor: 4.169
Authors: Ismael Valladolid-Acebes; Karin Åvall; Patricia Recio-López; Noah Moruzzi; Galyna Bryzgalova; Marie Björnholm; Anna Krook; Elena Fauste Alonso; Madelene Ericsson; Fredrik Landfors; Stefan K Nilsson; Per-Olof Berggren; Lisa Juntti-Berggren Journal: Sci Adv Date: 2021-03-12 Impact factor: 14.136
Authors: Elena G Bernea; Viorel I Suica; Elena Uyy; Aurel Cerveanu-Hogas; Raluca M Boteanu; Luminita Ivan; Iuliana Ceausu; Doina A Mihai; Constantin Ionescu-Tîrgoviște; Felicia Antohe Journal: Molecules Date: 2022-08-26 Impact factor: 4.927
Authors: Gabriele Mocciaro; Simona D'Amore; Benjamin Jenkins; Richard Kay; Antonio Murgia; Luis Vicente Herrera-Marcos; Stefanie Neun; Alice P Sowton; Zoe Hall; Susana Alejandra Palma-Duran; Giuseppe Palasciano; Frank Reimann; Andrew Murray; Patrizia Suppressa; Carlo Sabbà; Antonio Moschetta; Albert Koulman; Julian L Griffin; Michele Vacca Journal: Int J Mol Sci Date: 2022-06-17 Impact factor: 6.208
Authors: Sun Min Kim; Byoung Kyu Cho; Byoung Jae Kim; Ha Yun Lee; Errol R Norwitz; Min Jueng Kang; Seung Mi Lee; Chan Wook Park; Jong Kwan Jun; Eugene C Yi; Joong Shin Park Journal: J Korean Med Sci Date: 2020-03-16 Impact factor: 2.153